Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BF.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-630.996US
BQ.1.1.43NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-630.996US
BE.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23292.7US
BA.5.2.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.283NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
ED.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
B.1.1.214NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.284NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.47NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.351.3 (Beta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-25183.9US
BF.7.4.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-630.996US
ML.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.318NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
R.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26313.4US
AY.29 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.51NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.564.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.230NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AE.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.442NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.423NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.438.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.43NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AE.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.42NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
N.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.106NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.75NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.589NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.450NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.593NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.335NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.169NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.53NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.535NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.36NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.334NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.345NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23143.5US
AE.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
D.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.407NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used